Background: FGF-2 induces EMT in PTECs, and HPSE regulates HS/syndecans. Results: The lack of HPSE prevents FGF-2-induced EMT; FGF-2 induces EMT through PI3K/AKT and produces an autocrine loop. Conclusion: HPSE is necessary for FGF-2 to produce EMT, to activate FGF-2 intracellular signaling, and to regulate its autocrine loop. Significance: HPSE is an interesting pharmacological target for the prevention of renal fibrosis.
The epithelial-mesenchymal transition (EMT) of proximal tubular epithelial cells (PTECs) into myofibroblasts contributes to the establishment of fibrosis that leads to end stage renal disease. FGF-2 induces EMT in PTECs. Because the interaction between FGF-2 and its receptor is mediated by heparan sulfate (HS) and syndecans, we speculated that a deranged HS/syndecans regulation impairs FGF-2 activity.
Heparanase is crucial for the correct turnover of HS/syndecans. The aim of the present study was to assess the role of heparanase on epithelial-mesenchymal transition induced by FGF-2 in renal tubular cells. In human kidney 2 (HK2) PTEC cultures, although FGF-2 induces EMT in the wild-type clone, it is ineffective in heparanase-silenced cells. The FGF-2 induced EMT is through a stable activation of PI3K/AKT which is only transient in heparanase-silenced cells. In PTECs, FGF-2 induces an autocrine loop which sustains its signal through multiple mechanisms (reduction in syndecan-1, increase in heparanase, and matrix metalloproteinase 9). Thus, heparanase is necessary for FGF-2 to produce EMT in PTECs and to sustain FGF-2 intracellular signaling. Heparanase contributes to a synergistic loop for handling syndecan-1, facilitating FGF-2 induced-EMT. In conclusion, heparanase plays a role in the tubular-interstitial compartment favoring the FGF-2-dependent EMT of tubular cells. Hence, heparanase is an interesting pharmacological target for the prevention of renal fibrosis.
Tubulo-interstitial fibrosis is a structural marker of chronic, progressive kidney disease (1) , and the degree of tubulo-interstitial scarring is an excellent prognostic marker for end stage renal disease (2) . Epithelial-mesenchymal cell transition (EMT) 2 is a phenomenon that plays a central part in this process. The transdifferentiation of tubular epithelial cells implies the loss of epithelial characteristics by tubulocytes and the appearance of proteins and biological features associated with a mesenchymal phenotype (3, 4) . Epithelial cells in transition become mobile, and vimentin (VIM) is up-regulated together with ␣-smooth muscle actin (␣-SMA) (5) . Following cytoskeleton remodeling, the release of matrix metalloproteinases (MMPs) and tubular basement membrane disruption, cells with an acquired myofibroblast profile develop the ability to migrate into the interstitium. EMT occurs in response to several factors: hypoxia, reactive oxygen species, advanced glycation end products, MMPs, and numerous profibrotic cytokines and growth factors (6 -8) .
Fibroblast growth factor-2 (FGF-2), in particular, is an important trigger of EMT. It induces cell motility, the expression of VIM and ␣-SMA, the release of MMP-9 and MMP-2, and it reduces the expression of cytokeratin and E-cadherin in proximal tubular epithelium (9) .
In most cell types, intracellular signaling by FGF-2 takes place via the MAP kinase pathway (which includes ERK1/2, p38, and JNK kinase), the PI3K/AKT and the phospholipase C␥ pathways; the activation of ERK1/2 and p38 has been observed in most cell types, whereas that of the others is cell-specific (10, 11) . Of note, the PI3K/AKT pathway has been linked to FGF-2-induced EMT (12) .
Heparan sulfate (HS) is required for FGF-2 signaling. In particular, syndecans are common HS proteoglycans (PGs) that regulate FGF-2 signaling, acting as co-receptors and enabling the growth factor to bind the tyrosine kinase FGF-2 receptor. Syndecans (SDCs) form a family of four transmembrane core proteins (syndecan-1, -2, -3, and -4). Their extracellular domain has attachment sites for three to five HS chains. The HSPG most abundant in renal tubular epithelial cells is syndecan-1 (SDC1) and, although its down-regulation leads to EMT (13) , its overexpression in fibroblasts prevents the mitogenic activity of FGF-2 (14) . Under certain circumstances, heparanase (HPSE) can convert the SDC1 ectodomain from an inhibitor into an activator of FGF-2 (15) .
HPSE is an endo-␤-D-glucuronidase that cleaves HS chains participating in extracellular matrix remodeling and degradation. There are also reports of HPSE activities unrelated to cleaving, which influence intracellular signaling cascades and lead to selective protein kinase activation and gene transcription (16) . It has also recently been observed that HPSE can regulate nuclear SDC1 and subsequently influence histone acetyltransferase activity (HAT) (17) .
Experimental findings suggest that a tight functional connection exists among HPSE, SDC1, and FGF-2. In particular, HPSE regulates SDC1 clustering, shedding, and mitogen binding, and all three molecules could be co-localized in the nucleus (18, 19) . It has also been shown that HPSE could modulate FGF-2 binding through HS degradation (20) .
HPSE is reportedly involved in the pathogenesis of several proteinuric diseases (21) . Although it is generally considered a "glomerular player," essentially involved in the pathogenesis of altered glomerular permselectivity and proteinuria, our recently obtained data show that it has a role in tubular cell biology, in both normal and pathological conditions (21) .
The present study investigates whether an altered HPSE activity induces the typical cellular changes of EMT in human proximal tubular epithelial cells (PTECs) by affecting the interplay among HPSE, SDC, and FGF-2. A stably HPSE-silenced PTEC line was generated that exhibits an increased expression of HS and SDC1 on the cell membrane (22) .
Our results show that HPSE is crucial to the induction of EMT by FGF-2 in PTEC. The findings presented in this paper suggest that HPSE is also an actor in the pathogenesis of tubulointerstitial changes that eventually lead to end stage kidney disease.
EXPERIMENTAL PROCEDURES
Cell Cultures-The human renal proximal tubular cell line, HK2 (human kidney 2), was grown in DMEM-F12 (EuroClone) (17.5 mM glucose) supplemented with 10% fetal bovine serum (Biochrom AG), 2 mM L-glutamine, penicillin (100 units/ml), and streptomycin (100 g/ml) and maintained at 37°C in a 5% CO 2 water-saturated atmosphere. A stably HPSE-silenced HK2 cell line was obtained by transfection with shRNA plasmid targeting human HPSE (NM_006665) purchased from OriGene, as recently described elsewhere. These cells display an increase in HS and SDC1 (22) . HPSE-silenced HK2 cells were grown in the same medium of wild-type (WT) HK2 cells supplemented with 0.75 g/ml puromycin.
Cell Treatment-Cells were grown to subconfluence and starved for 24 h in serum-free medium and then cultured in serum-free medium with 10 ng/ml FGF-2 (BD Biosciences) treatments for a further 6 or 24 h. Experiments were performed with and without adding the PI3K pathway inhibitor wortmannin (1 M) (Calbiochem), the HAT inhibitor anacardic acid (20 M) (Santa Cruz Biotechnology), and the HPSE inhibitor low molecular weight heparin (50 g/ml) (Alfa Wassermann) 30 min before the FGF-2 treatment.
Transfection of AKT1/2 siRNA-Cells were transiently silenced for AKT by transfecting them with AKT1/2 siRNA (sc43609; Santa Cruz Biotechnology) and a control siRNA. The siRNAs were reconstituted and transfected into the WT HK2 cells using the TransIT-LT1 transfection reagent (Mirus) according to the manufacturer's instructions.
mRNA Expression Analysis-Total RNA was extracted from the cell monolayer using the GenElute Mammalian Total RNA Miniprep kit (Sigma-Aldrich) including DNase treatment (DNase70; Sigma). Yield and purity were checked using the Nanodrop (EuroClone), and total RNA from each sample was reverse-transcribed into cDNA using SuperScript II reverse transcriptase (Invitrogen). Real-time PCR was performed on an ABI-Prism 7500 using Power SYBR Green Master Mix 2ϫ (Applied Biosystems) A quantitative analysis was performed to evaluate expression fibronectin (FN), VIM, MMP-9, ␣-SMA, HPSE, and SDC1 and normalized to GAPDH. The forward and reverse primer sequences were: ␣-SMA forward, GAAGAAG-AGGACAGCACTG and reverse, TCCCATTCCCACCAT-CAC; FN forward, GTGTGTTGGGAATGGTCGTG and reverse, GACGCTTGTGGAATGTGTCG; VIM forward, AAAACACCCTGCAATCTTTCAGA and reverse, CACTTT-GCGTTCAAGGTCAAGAC; MMP-9 forward, CCTGGAGA-CCTGAGAACCAATC and reverse, CACCCGAGTGTAA-CCATAGC; HPSE forward, ATTTGAATGGACGGACTGC and reverse, GTTTCTCCTAACCAGACCTTC; SDC1 forward, GAAGATCAAGATGGCTCTGGG and reverse, GTTC-TGGAGACGTGGGAATAG; GAPDH forward, ACACCCA-CTCCTCCACCTTT and reverse, TCCACCACCCTGTTGC-TGTA.
The comparative Ct method (⌬⌬Ct) was used to quantify gene expression, and the relative quantification was calculated as 2
Ϫ⌬⌬Ct . Melting curves analysis was used to avoid any presence of nonspecific amplification products.
Western Blotting-For ERK, pERK, AKT, and pAKT analysis, cells were grown in serum-free medium for 24 h, then treated with 10 ng/ml FGF-2 for 0, 1, 2, 5, 10, or 20 min. The cells were treated in lysis buffer (50 mM Tris-HCl, pH 5.0, 150 mM NaCl, 0.5% Triton X-100) with Complete protease inhibitor mixture (Roche Applied Science) and phosphatase inhibitor cocktails 1 and 2 (Sigma-Aldrich) and quantified using the Bio-Rad protein assay.
Briefly, equal amounts of proteins were treated in reducing sample buffer and denatured for 10 min at 100°C. Protein samples were then resolved in 10% SDS-PAGE and electrotransferred to nitrocellulose membranes. Nonspecific binding was blocked for 1 h at room temperature with nonfat milk (5%) in TBST buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1 ϫ Tween 20).
Membranes were exposed to primary antibody overnight at 4°C and incubated with a secondary peroxidase-conjugated antibody for 1 h at room temperature. The signal was detected with the SuperSignals West Pico Chemiluminescent substrate solution (Pierce) according to the manufacturer's instructions.
The primary antibodies were sc-8312 and sc-7985-R (Santa Cruz Biotechnology) for AKT and pAKT, and 9102 and 9101 (Cell Signaling) for ERK and pERK, respectively. The secondary antibody was 401353 (Calbiochem). The primary antibodies were diluted 1:1000, the secondary antibodies 1:5000. Bands were analyzed by the ImageJ software (National Institutes of Health).
Immunofluorescence for ␣-SMA and Filamentous Actin Fibers-WT and HPSE-silenced cells were seeded in 22-mm glass dishes and cultured to subconfluence, serum-starved for 24 h, and then incubated with or without 10 ng/ml FGF-2 for 24 h to analyze ␣-SMA and for 5 days to analyze filamentous actin (F-actin). Cells fixed in 4% paraformaldehyde and permeabilized. For ␣-SMA staining, the cells were incubated for 1 h at 37°C with the primary antibody (mouse anti-␣-smooth muscle actin, 1A4, Sigma) in PBS with 1% BSA, then washed three times for 5 min with PBS before incubating them for 1 h at 37°C with the secondary antibody (goat anti-mouse IgG-FITC; Millipore) in PBS with 1% BSA. For F-actin staining, cells were incubated with Alexa Fluor 350-conjugated phalloidin (Molecular Probes) for 20 min at room temperature.
ELISA for HPSE Activity-HPSE activity was quantified using a HPSE assay kit from AMS Biotechnology (Milton, Abingdon) in total cell lysates and cell culture supernatants, according to the manufacturer's instructions. Briefly, the ELISA plate (with covalently bound biotinylated HS) was rehydrated with PBS at room temperature for 30 min. The PBS was removed, and 50 l of the reaction buffer and 50 l of the samples were added to each well. The plate was incubated for an h at 37°C, after which each well was washed four times with PBT (PBS ϩ 0.1% v/v Tween 20) and twice with PBS. Then 100 l of the Strep-HRP complex was added to each well, and the plate was incubated for an h at room temperature on a shaker. The plate was washed five times with PBS, and then 100 l of peroxidase substrate was added at room temperature. The plate was shaken gently, and the absorbance was determined at 450 nm in an ELISA plate reader. The activity of each sample was calculated as recommended by the manufacturer and represented as nanograms of HS removed per minute (23) . To prepare conditioned media, cells were starved for 24 h in serum-free medium and then incubated for another 24 h in serum-free medium with or without 10 ng/ml FGF-2. The media were then collected and clarified by centrifugation at 2000 ϫ g for 2 min. Platelet protein extract, diluted 1:100, was used as a positive control.
Zymography-Gelatin substrate zymography was used to assess MMP-9 activity. Conditioned media were prepared by incubating subconfluent cells in serum-free medium for 24 h, then with or without 10 ng/ml FGF-2 for a further 24 h. Zymography was carried out using standard procedures (24) . Equal amounts of conditioned media were resolved in nonreducing sample buffer on 10% SDS-polyacrylamide gels co-polymerized with 0.1% gelatin. After electrophoresis, the gels were washed two times for 30 min in 2.5% Triton X-100 at room temperature to remove SDS, then equilibrated for 30 min in collagenase buffer (50 mM Tris, 200 mM NaCl, 5 mM CaCl 2 , and 0.02% Triton X-100, pH 7.4), and finally incubated overnight with fresh collagenase buffer at 37°C. After incubation, gels were stained in 0.1% Coomassie Brilliant Blue R-250, 30% MetOH/10% acetic acid for 1 h and destained in 30% MetOH/10% acetic acid. Digestion bands were analyzed using ImageJ software.
Scratch Assay-The migration ability of HK2 cells was evaluated by means of a scratch assay. A denuded area was generated on quiescent cell monolayers of HK2 cells by scratching with a sterile pipette tip. The monolayer was washed twice with PBS and then incubated with medium (2% FCS), with or without 10 ng/ml FGF-2. The cells were photographed at different time points. The width of the scratch was measured in three different places on the photograph to obtain a mean value, and migration was recorded as the difference (in mllimeters Ϫ1 ) between the measurement at the baseline and after 24 h (25) .
HAT Activity Assay-The HAT activity in the nuclear extract was quantified using the colorimetric HAT activity assay kit (Abcam) according to the manufacturer's instructions. Briefly, 30 g of nuclear extract was incubated with HAT substrates I and II and NADH-generating enzyme in HAT assay buffer for 2 h at 37°C. Absorbance was determined at 450 nm in an ELISA plate reader. To obtain nuclear extract, WT and HPSE-silenced cells were starved for 24 h in serum-free medium and then incubated for another 24 h in serum-free medium with or without 10 ng/ml FGF-2. Detached cells were washed with ice-cold PBS and resuspended in buffer A (10 mM HEPES, 10 mM NaCl, 3 mM MgCl 2 , 1 mM EGTA, 0.1% Triton X-100, pH 7.5, supplemented with 50 mM NaF, 1 mM Na 3 VO 4 , 1 mM DTT, 1 mM PMSF, and Complete protease inhibitor mixture) on ice for 40 min, then centrifuged at 2400 ϫ g for 10 min. The pellets containing the nuclei were resuspended in buffer B (25 mM HEPES, 300 mM NaCl, 5 mM MgCl 2 , 1 mM EGTA, 20% glycerol, pH 7.4, supplemented with 50 mM NaF, 1 mM Na 3 VO 4 , 1 mM DTT, 1 mM PMSF, and Complete protease inhibitor mixture) on ice for 60 min. The lysates were centrifuged at 12,000 ϫ g for 20 min, the supernatants were collected, and the amount of nuclear protein was measured using the Bio-Rad reagent (26) .
Statistics-Means Ϯ S.D. of the real-time PCR data were calculated with Rest2009 software. Differences between WT and HPSE-silenced cells, or between treated and untreated cells, were compared using Student's t test. A p value Յ 0.05 was set as the level of significance for all tests.
RESULTS
The effect of FGF-2 on a number of parameters was investigated in WT HK2 cells and HPSE-silenced HK2 cells.
Expression of Mesenchymal Markers-WT and HPSE-silenced cells were treated with FGF-2 for 6 h, and mesenchymal marker expression was evaluated by quantitative real-time PCR. HPSE-silenced cells exhibited the same basal ␣-SMA expression as WT cells. Treatment with FGF-2 triggered a significant increase in ␣-SMA expression in WT cells, but not in HPSE-silenced cells (Fig. 1A) . The induction of ␣-SMA protein synthesis in WT but not in HPSE-silenced cells after FGF-2 treatment was also confirmed by immunofluorescence staining (Fig. 1B) . Likewise, when FN and VIM gene expression was assessed, WT and HPSE-silenced cells displayed similar basal expression levels, which were significantly up-regulated by FGF-2 in WT tubular cells, but not in HPSE-silenced cells (Fig. 2) .
MMP-9 Gene Expression and Activity-Gene expression analysis showed a lower basal MMP-9 expression in HPSE-silenced cells than in WT cells, and FGF-2 induced a significant increase in MMP-9 gene expression in WT tubular cells, but produced no effect in the HPSE-silenced clone (Fig. 3A) .
Extracellular MMP-9 activity, assessed by gelatin zymography on conditioned media, reflected the gene expression pattern. In particular, HPSE-silenced cells showed a lower basal MMP-9 activity than WT cells, and FGF-2 treatment induced a significant (2-fold) increase in MMP-9 activity only in the WT tubular cells, whereas it remained at basal levels in HPSE-silenced cells (Fig. 3B) . Morphological Changes and Cell Motility-When grown in serum-free conditions WT and HPSE-silenced cells appeared as a typical "cobblestone" monolayer. FGF-2 treatment determined marked changes in WT HK2 cell morphology but not in HPSE-silenced cells. WT HK2 cells, after FGF-2 prolonged exposition, lost their regular epithelial appearance, becoming elongated and acquiring a spindle-shape morphology. Untreated WT and HPSE-silenced HK2 cells displayed the typical epithelial actin cytoskeleton organization with randomly oriented fibers into the cytoplasm and the band of junctional actin close to the cell membrane. FGF-2 caused the disappearance of junctional actin and the increase of stress fibers from side to side of the cells only in WT HK2 cells (Fig. 4A) . A scratch assay showed that although HPSE-silenced cells have the same basal migration capacity as WT tubular cells, they did not respond to FGF-2 stimulation (which almost doubled the motility of the WT cells) (Fig. 4B) .
Effects of FGF-2 on Heparanase and SDC1-We analyzed SDC1 and HPSE expression to gain a better idea of the effects of FGF-2 on HSPG "metabolism." As expected, the HPSEsilenced cells showed a significantly lower HPSE expression than the WT HK2 cells. Treatment with FGF-2 for 6 h induced a significant increase in HPSE expression in WT cells, but not in HPSE-silenced cells, which remained at the low basal levels (Fig. 5A) .
The gene expression pattern reflected HPSE activity: endoglycosidase activity was significantly impaired in HPSEsilenced cells, in both total cell lysates and conditioned media. Treatment with FGF-2 prompted an increase in HPSE activity in WT HK2 protein extract and conditioned media, but had no effect on HPSE-silenced HK2 cells (Fig. 5, B and C) .
Our results also show that FGF-2 significantly reduced SDC1 expression only in WT HK2, whereas it had no effect on HPSEsilenced cells (which displayed a significant basal up-regulation of SDC1 expression compared with WT cells) (22) (Fig. 6) .
Role of HPSE Activity in FGF-2-induced EMT-To demonstrate the contribution of HPSE activity to FGF-2-induced EMT, we assessed the effect of low molecular weight heparin as the HPSE inhibitor. Gene expression analysis showed that the heparin treatment prevents FGF-2-induced ␣-SMA, VIM, FN, and MMP-9 increase as well as HPSE up-regulation and SDC1 decrease (Fig. 7) .
FGF-2 Signaling-We analyzed the effects of FGF-2 in stimulating the ERK and PI3K/AKT pathways. Stimulation with 10 ng/ml FGF-2 failed to induce ERK1/2 phosphorylation in either WT or HPSE-silenced cells (Fig. 8A) . However, FGF-2 at the same dosage induced a rapid AKT phosphorylation (within 1 min) in both cell lines; but whereas the signal remained high in WT cells for at least 20 min, it dropped rapidly in HPSE-silenced cells, returning to base-line levels within 20 min (Fig.  8B) .
To see whether FGF-2 exerts its pro-EMT effect via the PI3K/AKT pathway in tubular cells, the expression of several EMT-associated markers was assessed in combination with the specific PI3K inhibitor wortmannin and in cells silenced for AKT. As expected, WT HK2 cells transfected with anti-AKT1/2 siRNAs disclosed a significant reduction in total AKT. FGF-2 induced a weaker AKT phosphorylation in AKT-silenced cells than in WT cells (Fig. 9) .
WT cells, preincubated with or without wortmannin, and AKT-silenced cells were treated with FGF-2 for 6 h before the expression of EMT-associated mesenchymal markers was eval- uated by quantitative real-time PCR. Gene expression analysis showed that wortmannin and AKT silencing did not affect the basal levels of ␣-SMA, VIM, FN, MMP-9, HPSE, and SDC1.
Our results show that the ␣-SMA up-regulation induced by FGF-2 was restored to basal levels by wortmannin and AKT silencing (Fig. 10A) . The VIM, FN, and MMP-9 overexpression induced by FGF-2 was also canceled by both wortmannin and AKT silencing (Fig. 10, B-D) .
Whether HPSE and SDC1 expression was regulated by FGF-2 via the PI3K/AKT pathway was also investigated. Wortmannin and AKT silencing was able to inhibit fully any FGF-2-induced HPSE overexpression (Fig. 11A) and SDC1 down-regulation (Fig. 11B) .
HAT Activity-Because a recent work showed that the amount of nuclear SDC1 regulates HAT activity and gene expression (17) and because HPSE-silenced cells display an increase in nuclear SDC1 (23), we looked for any differences in HAT activity in WT and HPSE-silenced cells.
We also assessed the contribution of HAT to FGF-2-induced EMT. Our results show that HPSE-silenced cells had a significantly lower HAT activity than WT cells and that treatment with FGF-2 had no effect on HAT activity in either WT or HPSE-silenced cells (Fig. 12A) .
Gene expression analysis showed that inhibiting HAT with anacardic acid in tubular WT cells does not prevent the increase in ␣-SMA, VIM, FN, and HPSE, nor does it prevent the reduction in SDC1 after FGF-2 treatment. Inhibiting HAT does not alter the basal level of expression of these genes, but it does induce a significant reduction in MMP-9 in both FGF-2-treated and untreated cells (Fig. 12B) .
DISCUSSION
The EMT of renal tubular cells into myofibroblasts contributes substantially to the establishment of a fibrotic condition that leads to end stage renal disease (27) . FGF-2 has been identified as a growth factor capable of inducing EMT in PTECs (9) . Because the interaction between FGF-2 and its tyrosine kinase receptor is mediated and influenced by HS and the HSPG syndecans, we speculated that a deranged HS/HSPGs regulation could impair FGF-2 activity.
An abnormal HS/HSPG metabolism has been seen in renal disease, especially in diabetic nephropathy (28) , and a deranged HS/HSPG regulation and interaction with FGF-2 could be of relevance in renal pathology. In fact, Morita et al. recorded the expression of particular HSPG structures and an increased FGF-2 binding domain in extracellular matrix HS in renal biopsies from diseased kidneys (29) . In addition, the number of low affinity FGF-2 receptors (i.e. syndecans) was found altered in the kidney of an experimental model of HIV-associated glomerulitis, suggesting a role for a deranged FGF-2 loop in the pathogenesis of the disease (30) .
The factors involved in HS regulation and syndecan expression on the cell membrane are not completely known, but HPSE seems to have a pivotal role. A recent study of ours showed that typical features of diabetic nephropathy, i.e. albumin(uria) and advanced glycation end products, are strong modulators of HS and SDC expression via a phenomenon relating to HPSE-dependent mechanisms. In fact, the HPSE up-regulation in tubular cells induced by albumin and advanced glycation end prod- ucts leads to a down-regulation of both HS and SDC1. Hence, the present study aimed to shed light on the role of HPSE in tuning the FGF-2 loop in renal EMT.
Here, we demonstrate that FGF-2 needs the expression of HPSE to induce EMT in tubular cells. As observed previously by Strutz et al. (9) , challenging WT PTECs with FGF-2 prompted a significant increase in ␣-SMA, VIM, and FN expression, reflecting a transition toward the mesenchymal phenotype. In our cellular model of HPSE-silenced cells, however, ␣-SMA, VIM, and FN expression (the basal expression of which was much the same as in WT PTEC) did not increase in response to FGF-2 stimulation. Our data support previous findings in melanoma cells that HPSE modulates FGF-2 activity (20) .
It has also been reported that FGF-2 increases MMP-9 activity in tubular cells. Our present findings in WT tubular cells confirm previous reports (9) of FGF-2 inducing a significant increase in MMP-9 expression and activity, with a parallel stimulation of cell motility, two further proofs of the induction of EMT by FGF-2. As expected, FGF-2 did not increase MMP-9 expression and activity in HPSE-silenced cells, and no cell motility was promoted. Moreover, FGF-2 transformed WT but not HPSE-silenced tubular cell morphology from a typical epithelial cobblestone monolayer toward a mesenchymal phenotype. These changes include cell elongation, acquisition of a spindle-shaped morphology, loss of junctional actin, and increase of stress fibers. These data show that transition to the mesenchymal phenotype is precluded in HPSE-silenced cells.
The role of HPSE on FGF-2 activity is most likely related to its effects on HS/HSPG regulation. We showed previously that HPSE-silenced cell lines display a significant increase in HS. At least two mechanisms may explain this up-regulation. First, endoglycosidase activity is reduced in HPSE-silenced cells at both intracellular and extracellular levels, thereby decreasing HS turnover. Second, the expression of the SDC1 HSPG is increased (22) . Since Mali et al. (14) demonstrated that SDC1 inhibits the effects of FGF-2, an increased expression of HS/HSPG syndecan on the cell surface of HPSE-silenced cells may well explain our findings. It is worth noting that the effects of HPSE in these systems depends on its activity, so using HPSE inhibitors could be of relevance in controlling fibrotic nephropathies. In the light of a recent work showing that HPSE is able to promote gene expression (e.g. MMP-9) by regulating nuclear SDC1, which in turn regulates HAT activity (17), we found that HPSE-silenced cells, which display an increased nuclear SDC1 (22) , reveal a significant reduction in HAT activity. Together with the observation that inhibiting HAT activity in WT cells leads to a reduction in MMP-9 expression, this could explain the lower basal level of MMP-9 expression in HPSE-silenced cells. However, HAT does not seem to be implicated in FGF-2-induced EMT, given that FGF-2 does not influence HAT activity, and inhibiting HAT does not prevent EMT.
To investigate further the role of HPSE on EMT induced by FGF-2, we analyzed whether HPSE influences the FGF-2 signaling pathways. FGF-2 primes three principal signaling pathways, i.e. the phospholipase C␥, the MAPK (ERK1/2), and the PI3K/ AKT pathway; we considered the latter two because they are involved in several examples of EMT (31) . We found that FGF-2 did not activate the ERK1/2 pathway in either WT or HPSEsilenced tubular cells, but it did induce a rapid and persistent activation of AKT in WT cells. That the PI3K/AKT pathway is the signaling pathway mediating FGF-2-induced EMT in PTECs is confirmed by experiments with the specific PI3K inhibitor wortmannin, and with AKT silencing: both prevented any increase in ␣-SMA, FN, VIM, and MMP-9 expression in FGF-2-treated WT cells.
The profile of AKT activation induced by FGF-2 is quite different in HPSE-silenced cells. The initial activation (comparable with the situation seen in WT cells) rapidly decays to baseline levels. This different response to FGF-2 between WT and HPSE-silenced cells suggests that FGF-2 signaling and its downstream effects (i.e. EMT) are influenced by HPSE or by some other molecule regulated by HPSE. One hypothesis is that the presence of an increased amount of SDC1 on the cell surface of HPSE-silenced cells impairs FGF-2 binding to its tyrosine kinase receptors, consistently with the inhibitory role of syndecan discovered by Mali et al. (14) . A second hypothesis is that a different interaction between FGF-2 and the HSPG (which may be differently expressed on the HPSE-silenced cells) enables the stimulation of an AKT-dephosphorylating signaling pathway with a slight delay vis-à-vis the activation of the PI3K/AKT pathway (32) . Whereas HPSE and the consequent HS/HSPG regulation have a role in the cascade of phenomena triggered by FGF-2, the latter also influences HPSE and SDC1 expression in tubular cells. In particular, FGF-2 increases HPSE expression and activity and generates a reduction in SDC1, both of which are also under PI3K/AKT control.
Taken together, our results highlight two main biological phenomena. First, a basal expression of HPSE is needed to sustain FGF-2 signaling and to support our claim that HPSE down- regulation makes tubular cells insensitive to FGF-2 (despite an initial transient activation of the PI3K/AKT pathway), making them resistant to EMT. Second, FGF-2 seems to maintain its cellular effects by means of a positive autocrine loop. Interpreting cell surface SDC1 as an FGF-2 inhibitor (14), FGF-2 reduces its expression, and this therefore appears to be a strategy for amplifying FGF-2 binding and signaling. It is also worth noting that MMP-9 is a SDC1 sheddase (33) , and HPSE can convert soluble SDC1 fragments from FGF-2 signaling inhibitors into potent activators (15) . In the light of these considerations, the FGF-2-dependent increase in both HPSE and MMP-9 expression and activity can be seen as a synergistic loop for handling SDC1 to facilitate the effect of FGF-2 on EMT, possibly determining a vicious circle that contributes to end stage kidney disease. There are other examples of such a distortion of physiological mechanisms. In the case of TGF-␤1, for instance (the only growth factor capable of generating a positive feedback on its own synthesis) (34) , it is probably a failure to shut down its production that results in an accelerated renal fibrosis (35) .
Our findings are of interest to renal pathology. In the scenario of a progressive fibrotic disease like diabetic nephropathy, factors such as advanced glycation end products and albuminuria increase HPSE expression and reduce SDC1 in tubular cells, generating a condition of pro-FGF-2-dependent EMT. In addition, HPSE (which is increased in several proteinuric glomerular diseases) is responsible for glomerular damage (36) and proteinuria, which in turn increase HPSE and reduce SDC1 in the renal tubule, favoring an FGF-2-dependent EMT. Given such a self-fueling regimen, these mechanisms could drive renal fibrosis, and HPSE could be an interesting pharmacological target for the treatment of chronic kidney disease.
